



Barcelona BioMed Conference Proximity-inducing pharmacology: Targeted protein degradation and beyond 22-24 May, 2023

Monday, 22 May

- 8.30 Registration
- 9.00 Welcome by Directorate of IRB Barcelona and organizers (Dr. Cristina Mayor-Ruiz and Dr. Georg E. Winter)

Session 1: Proteolysis Targeting Chimeras (PROTACs) Chair: Dr. Marie-Helene Helene Larraufie (Barcelona, Spain)

- 9.15 Interrogating the Druggable Proteome with Proximity Pharmacology Dr. Fleur M. Ferguson, University of California San Diego (San Diego, CA, USA)
- 9.45 **Targeted Protein Degradation at the academic-industry interface** Dr. William Farnaby, University of Dundee (Dundee, UK)
- 10.15 Advancing targeted protein degraders and bringing them into the clinic Dr. Danette L. Daniels, Foghorn Therapeutics (CA, MA, USA)
- 10.45 -11.30 Coffee break and poster session
- 11.30 <u>Short talk 1:</u> Directing the E3 ligase pair SIAH1/2 towards degradation of neosubstrates using covalent PROTACs Dr. Lena Münzker, Boehringer Ingelheim RCV GmbH & Co KG (Vienna, Austria)
- 11.45 How PROTACs Work: Molecular Recognition and Design Principles Dr. Alessio Ciulli, University of Dundee (Dundee, UK)

- 12.15 What's Next? Looking beyond PROTACs Dr. Craig M. Crews, Yale University (New Heaven, CT, USA)
- 12.45 <u>Short talk 2</u>: An intramolecular bivalent degrader glues an intrinsic BRD4-DCAF16 interaction Dr. Angus Cowan, University of Dundee (Dundee, UK)
- 13.00 -14.30 Lunch and poster session

Session 2: Molecular glues

Chair: Dr. Jay Bradner (CA, MA, USA)

- 14.30 Chasing molecular glues and overcoming broad resistance to degraders Dr. Cristina Mayor-Ruiz, IRB Barcelona (Barcelona, Spain)
- 15.00 <u>Short talk 4:</u> BTB_{BCL6} dimers as building blocks for reversible drug-induced protein oligomerization
 Dr. Mikołaj Słabicki, Broad Insitiute (Cambridge, MA, USA)
- 15.15 Identification and characterization of small-molecule degraders Dr. Georg E. Winter, CeMM (Vienna, Austria)
- 15.45 16.45 Coffee break and poster session
- 16.45 <u>Short talk 3</u>: Understanding cooperativity effects in the drug-dependent degradation of the Cereblon neosubtrate CK1 alpha Dr. Jordi Juárez-Jiménez, UB (Barcelona, Spain)
- 17.00 **Design principles for cyclin K molecular glue degraders** Dr. Nicolas H. Thomä, FMI (Basel, Switzerland)
- 17.30 Mechanism of action of velcrin small molecules Dr. Heidi Greulich, Broad Institute (Cambridge, MA, USA)
- 18.00 End of session

Tuesday, 23 May

Session 3: Targeted degradation beyond the proteasome Chair: Dr. Ingo Hartung (Darmstadt, Germany)

- 9.00 Targeting extracellular and membrane proteins for degradation via lysosome targeting chimeras (LYTACs) Dr. Green Ahn, Stanford University (Stanford, CA, USA)+
- 9.30 **BacPROTACs mediate targeted protein degradation in bacteria** Dr. Francesca E. Morreale, IMP, The Francis Crick Institute (London, UK)

- 10.00 <u>Short talk 5</u>: **Development of next generation AUtophagy TArgeting Chimeras** (AUTACs) to enable proximity induced degradation of mitochondria Niyaz Zaman, University College London (London, UK)
- 10:15 <u>Short talk 6</u>: Multicomponent Reaction-Based Approach to Novel Aryl Hydrocabon Receptor Activators, PROTACs and HomoPROTACs Dr. Ouldouz Ghashghaei, IBUB- UB (Barcelona, Spain)
- 10.30 -11.30 Coffee break and poster session
- 11.30 <u>Short talk 7:</u> Induced self-elimination of the Clp protease system as antibiotics strategy
 Dr. David M. Hoi, Institute of Molecular Pathology (Vienna, Austria)
- 11.45 **Targeting unexplored E3 ligases with small molecules** Dr. Carles Galdeano, UB Barcelona (Barcelona, Spain)
- 12:15 Target degradation of disease-causing RNAs with ribonuclease targeting chimeras (RiboTACs) Dr. Mathew Disney, UF Scripps Biomedical Research (La Jolla, CA, USA)

12:45-14.30 Lunch and poster session

Session 4: Inducing and removing post-translational modifications: ubiquitin and beyond

Chair: Dr. Ingo Hartung (Darmstadt, Germany)

- 14.30 **Two new ways to drug targets** Dr. Sayumi Yamazoe, Bristol-Myers Squibb (CA, USA)
- 15.00 **Reimagining Druggability using Chemoproteomic Platforms** Dr. Daniel K. Nomura, University of California, Berkeley (Berkeley, CA, USA)
- 15.30 <u>Short talk 8:</u> Development of a novel type of proteolytic chimera based on direct 26S proteasome targeting Dr. Bernat Crosas, IBMB-CSIC (Barcelona, Spain)
- 15.45 <u>Short talk 9</u>: **E3-ID: an innovative system to identify targets of E3 ligases** Dr. James D. Sutherland, CIC bioGUNE (Bizkaia, Spain)
- 16.00- 16.45 Coffee break and poster session
- 16.45 **Protein editing using small molecules** Dr. Amit Choudhary, Broad Institute (CA, MA, USA)
- 17:15 Chemoproteomic-Enabled Development of Proximity-Inducing Molecules Dr. Christopher G. Parker, The Scripps Research Institute (La Jolla, CA, USA)

- 17.45 <u>Short talk 10</u>: HiBiT-SpyTag: A minimal tag for covalent protein capture and degrader development Dr. Radosław P. Nowak, Dana-Farber Cancer Institute (Boston MA, USA)
- 18.00 End of session
- 20.30 Speakers dinner (Restaurant Can Pineda) (Sant Joan de Malta, 55)

Wednesday, 24 May

Session 5: Proximity-inducing pharmacology: new approaches and computational methods

Chair: Dr. Modesto Orozco (Barcelona, Spain)

- 9.00 <u>Short talk 11</u>: Target- and E3-driven discovery of molecular glue degraders via accelerated protein energy-landscape exploration Dr. Carles Perez-Lopez, IRB Barcelona (Barcelona, Spain)
- 9.15 <u>Short talk 12</u>: Finding all our switches: fast global mapping of the allosteric landscape for KRAS inhibition Dr. Ben Lehner, Wellcome Sanger Institute & CRG (Barcelona, Spain)
- 9.30 Assessing ternary complex formation for protein degradation Dr. Víctor Guallar, BSC/ ICREA (Barcelona, Spain)
- 10.00 Blending Chemistry and Biology to Enable Systems Pharmacology Dr. Patrick Aloy, IRB Barcelona/ ICREA (Barcelona, Spain)

10.30 -11.15 Coffee break and poster session

- 11.15 <u>Short talk 13</u>: Supercharging kinase turnover rationalizing non-obvious destabilization mechanisms
 Dr. Natalie S. Scholes, CeMM (Vienna, Austria)
- 11.30 <u>Short talk 14</u>: **Transcriptional chemical inducers of proximity to rewire cancer drivers** Sai Gourisankar, Stanford University (Stanford, CA, USA)
- 11.45 AI/ML-enabled global ligandability maps allow quantitative and qualitative drug interactome predictions Dr. Miquel Duran-Frigola, Ersilia Open Source Initiative (Cambridge, UK)
- 12.15 <u>Short talk 15</u>: **DEGRONOPEDIA a web server for proteome-wide inspection of degrons** Natalia A. Szulc, IIMCB (Warsaw, Poland)
- 12.30 Concluding remarks and end of conference